Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05880537 · ClinicalTrials.gov registry record
Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry
A clinical trial of End Stage Renal Disease, sponsored by LifeNet Health.
- Recruiting
- Registry status
- 100
- Enrollment target
- 4
- Study locations
NCT05880537: Recruiting study of End Stage Renal Disease, sponsored by LifeNet Health.
NCT05880537 is a study of End Stage Renal Disease that is actively recruiting participants, run by LifeNet Health. The registered enrollment target is 100 participants, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05880537, a study of End Stage Renal Disease, is actively recruiting participants, sponsored by LifeNet Health.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
Primary Outcome
Ultrasound proof of vessel patency and blood flow
Conditions Studied
Interventions
- OTHER Nexeon Arterial Venous Allograft
Study Locations (4)
California
- Olive View - UCLA Medical Center - Sylmar
- Harbor-UCLA Medical Center - Torrance
Alabama
- Infirmary Heath - Mobile
Virginia
- Sentara Norfolk General Hospital - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2027-12-15 |
What NCT05880537 shows while recruiting
NCT05880537 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower).
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Nexeon Arterial Venous Allograft is the first listed.
NCT05880537 reports a single indexed study location in California, Alabama, Virginia.
Frequently Asked Questions
What is clinical trial NCT05880537 about?
NCT05880537 is a clinical study titled "Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry". Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
What is the current status of trial NCT05880537?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-06-06. Estimated completion is 2027-12-15.
What conditions does trial NCT05880537 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT05880537?
The interventions under investigation include: Nexeon Arterial Venous Allograft (OTHER).
Who is sponsoring clinical trial NCT05880537?
This trial is sponsored by LifeNet Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05880537 being conducted?
This trial has 4 study locations across Alabama, California, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05880537's enrollment target sits among peer trials
100 34th of 86 higher than 50 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
RECRUITING
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI